News | Breast Imaging | March 29, 2018

ACR Recommends More Aggressive Breast Cancer Screening for Higher-Than-Average-Risk Women

All women recommended to undergo risk assessment by age 30; association now recommends annual breast MRI for particular subgroups

ACR Recommends More Aggressive Breast Cancer Screening for Higher-Than-Average-Risk Women

March 29, 2018 — The American College of Radiology (ACR) released new breast cancer screening guidelines recommending all women, especially black women and those of Ashkenazi Jewish descent, should undergo risk assessment by age 30. Assessing risk at this age would allow women at higher risk to be identified and begin earlier and more aggressive screening for breast cancer. In a separate recent analysis[i] from Harvard, black, Hispanic and Asian women have peak incidence of breast cancer in their 40s and should begin screening at least by age 40.

The ACR reaffirmed recommendations for annual breast magnetic resonance imaging (MRI) in the following groups, with slight refinements:

  • 1) Women with known or disease-causing BRCA1 mutation (or their untested first-degree relatives) should begin annual MRI at age 25. If MRI is performed annually, there is emerging evidence that the benefit of mammography is relatively small in such women prior to the age of 40;
  • 2) Women with other known disease-causing mutations (or their untested first-degree relatives), and those with a calculated lifetime risk of 20 percent or more, should begin annual MRI between age 25 and 30. Annual mammography is of benefit in those with BRCA2 mutations;
  • 3) Women with prior chest/mantle radiation therapy (cumulative dose of ≥ 10 Gy) before age 30 should begin MRI and annual mammography at age 25 or at least 8 years after completion of radiation, whichever is latest; and
  • 4) Women with a calculated lifetime risk of breast cancer of ≥ 20 percent. The Tyrer-Cuzick model was discussed as the most comprehensive and consistently accurate model for predicting risk and now includes fibroglandular breast density as a risk factor, though all models may over- or underestimate risk for a given individual.

The ACR newly endorses annual screening MRI in addition to annual mammography or tomosynthesis for women in the following situations (provided the patient has not had bilateral mastectomy):

  • Women with a personal history of breast cancer and dense breasts; and
  • All women diagnosed by age 50. A personal history of breast cancer is not included in risk models, but all women diagnosed with breast cancer at or before age 50 and treated with breast-conserving therapy have a ≥ 20 percent risk for a new breast cancer.

The ACR suggests annual MRI be considered in addition to annual mammography or tomosynthesis in women with a history of lobular carcinoma in situ (LCIS) or prior atypia (ADH, ALH, atypical papilloma), especially if other risk factors are present, though further study of the benefit of MRI is needed.

In women who meet guidelines for MRI screening but are unable to tolerate it and who have dense breasts, the ACR suggests ultrasound be considered in addition to annual mammography. Tomosynthesis is expected to reduce the benefit of supplemental screening ultrasound, depicting about half of the cancers that would have been seen only on ultrasound after 2-D mammography, though further study is warranted. If MRI is performed, there is no benefit to screening ultrasound.

For more information: www.acr.org

References

I. Stapleton SM, Oseni TO, Bababekov YJ, Hung Y, Chang DC. Race/Ethnicity and Age Distribution of Breast Cancer Diagnosis in the United States. JAMA Surg. Published online March 07, 2018. doi:10.1001/jamasurg.2018.0035

 

Related Content

Hologic, Inc. announced he U.S. launch of the SuperSonic MACH 40 ultrasound system, expanding the company’s suite of ultrasound technologies with its first premium, cart-based system.
News | Breast Imaging | July 08, 2020
July 8, 2020 — Hologic, Inc. announced he U.S.
In new QuickPoLL survey on imaging during the pandemic, responses were tallied from around 170 radiology administrators and business managers, who are part of an imagePRO panel created by The MarkeTech Group (TMTG), regarding the effects of COVID-19 on their business. TMTG is a research firm specializing in the medical device, healthcare and pharmaceutical industries.
Feature | Coronavirus (COVID-19) | June 30, 2020 | By Melinda Taschetta-Millane
VolparaEnterprise data analysis shows mammography screening volumes are quickly increasing
News | Mammography | June 09, 2020
June 9, 2020 — More than 75 percent of hospitals and imaging centers that perform mammography across the United State
Developed by medical AI company Lunit, Software detects breast cancer with 97% accuracy; Study in Lancet Digital Health shows that Lunit INSIGHT MMG-aided radiologists showed an increase in sensitivity

Lunit INSIGHT MMG

News | Artificial Intelligence | June 02, 2020
June 2, 2020 — Lunit announced that its artificia...
AI has the potential to help radiologists improve the efficiency and effectiveness of breast cancer imaging

Getty Images

Feature | Breast Imaging | May 28, 2020 | By January Lopez, M.D.
Headlines around the world the past several months declared that...
a Schematic of the system. The entire solid tumour is illuminated from four sides by a four-arm fibre bundle. A cylindrically focused linear array is designed to detect optoacoustic signals from the tumour. In vivo imaging is performed in conical scanning geometry by controlling the rotation and translation stages. The sensing part of the transducer array and the tumour are submerged in water to provide acoustic coupling. b Maximum intensity projections of the optoacoustic reconstruction of a phantom of pol

a Schematic of the system. The entire solid tumour is illuminated from four sides by a four-arm fibre bundle. A cylindrically focused linear array is designed to detect optoacoustic signals from the tumour. In vivo imaging is performed in conical scanning geometry by controlling the rotation and translation stages. The sensing part of the transducer array and the tumour are submerged in water to provide acoustic coupling. b Maximum intensity projections of the optoacoustic reconstruction of a phantom of polyethylene microspheres (diameter, 20 μm) dispersed in agar. The inset shows a zoomed-in view of the region boxed with a yellow dashed line. In addition, the yellow boxes are signal profiles along the xy and z axes across the microsphere centre, as well as the corresponding full width at half-maximum values. c Normalized absorption spectra of Hb, HbO2 and gold nanoparticles (AuNPs). The spectrum for the AuNPs was obtained using a USB4000 spectrometer (Ocean Optics, Dunedin, FL, USA), while the spectra for Hb and HbO2 were taken from http://omlc.org/spectra/haemoglobin/index.html. The vertical dashed lines indicate the five wavelengths used to stimulate the three absorbers: 710, 750, 780, 810 and 850 nm. Optoacoustic signals were filtered into a low-frequency band (red) and high-frequency band (green), which were used to reconstruct separate images.

News | Breast Imaging | May 26, 2020
May 26, 2020 — Breast cancer is the most common cancer in women.
Phone call and linkage-to-care-based intervention increases mammography uptake among primary care patients at an urban safety-net hospital

Getty Images

News | Mammography | May 22, 2020
May 22, 2020 — Telephone outreach coupled with scheduling assistance significantly increased...
The Breast Imaging and Reporting System (BI-RADS) was established by the American College of Radiology to help classify findings on mammography. Findings are classified based on the risk of breast cancer, with a BI-RADS 2 lesion being benign, or not cancerous, and BI-RADS 6 representing a lesion that is biopsy-proven to be malignant.

Getty Images

News | Breast Imaging | May 19, 2020
May 19, 2020 — Women with mammographically detected breast lesions that are probably benign should have follow-up sur
Podcast: Impact of COVID-19 on Breast Cancer Treatment with Dr. Andrea Madrigrano

Kubtec hosts a Podcast: Impact of COVID-19 on Breast Cancer Treatment with Andrea Madrigrano, M.D., as part of its public service campaign.

News | Coronavirus (COVID-19) | May 06, 2020
May 6, 2020 — The COVID-19 pandemic is an unprec